← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Shasqi, Inc.
San Francisco, CA
$9,091,553
Total funding
5
Grants
Funding over time
peak $3.1M · FY2021–25$5M$3.8M$2.5M$1.3M$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,091,553 · 5
By mechanism
R44$9,091,553 · 5
Investigators at Shasqi, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Antigen-targeted activation of Topo1 inhibitors via click chemistry$1,568,070
R44 · FY2024 · CA
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$1,376,786
R44 · FY2021 · CA
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$1,217,955
R44 · FY2024 · CA
Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$1,198,848
R44 · FY2021 · CA
CEACAM5-targeted activation of potent chemotherapeutics via bioorthogonal click chemistry$1,094,189
R44 · FY2025 · CA
Immune Biomarker Assessment and Manufacturing Development for SQ3370-001, a first-in-human phase I dose-escalation clinical trial to test a novel treatment against advanced solid tumors$801,129
R44 · FY2022 · CA
Antibody-guided localized activation of bioorthogonal protodrugs via click chemistry$781,732
R44 · FY2023 · CA
Antigen-targeted activation of Topo1 inhibitors via click chemistry$431,859
R44 · FY2025 · CA
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$322,142
R44 · FY2024 · CA
Assessing the safety and efficacy of SQ3370 in a phase 1b dose-expansion cohort at the recommended Phase 2 dose in patients with advanced sarcoma$298,843
R44 · FY2023 · CA